Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Saxenda in Bariatric Surgery Candidates
NCT06865365Phase 4Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- May 2025
- Primary completion
- Feb 2027
- Modality
- Peptides
01
Overview
Phase 4, randomised, open-label trial of liraglutide in obesity (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Percentage of Total Weight Loss at 6 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06865365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865365.